

BiolInvent Q2 2024 - Positive Development with BI-1206 and BI-1808

Redeye comments on BiolInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and solid tumours and from BI-1808 were presented during the quarter.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[BiolInvent Q2 2024 - Positive Development with BI-1206 and BI-1808](#)